ReviewThe Journal of frailty & aging2018
The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin Signaling and Implications for Clinical Trials.
Review in The Journal of frailty & aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Potential effect of Irisin on sarcopenia: a systematic review.BMC musculoskeletal disorders · 2025Pooled it
- Trial
- Effects of Resistance Exercise and Essential Amino Acid Intake on Muscle Quality, Myokine, and Inflammation Factors in Young Adult Males.Nutrients · 2024Trial
- Exerkines in precision management of metabolic diseases.Chinese medical journal · 2026Review
- Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives.Reviews in endocrine & metabolic disorders · 2026Review
- Epigenetic signatures of cardiometabolic risk in men: accelerated aging and differential methylation replicated across cohorts.Clinical epigenetics · 2026Article
- Association of Triglyceride-Glucose-Frailty Index with Cardiovascular Disease and All-Cause Mortality Incidence in Individuals with Cardiovascular-Kidney-Metabolic Syndrome Stages 0-3: A Nationwide Prospective Cohort Study.Journal of clinical medicine · 2026Article
- A High Dose of Short-term Intraperitoneal D-galactose-induced Aging Process in Male Rats.Annals of African medicine · 2026Article
- Myostatin Research: From Molecular Understanding to Clinical Translation for Musculoskeletal and Metabolic Disorders.International journal of molecular sciences · 2026Review
- Ubiquitin-Specific Protease 2 (USP2) as a Modulator of Energy Metabolism: A Review of Studies Using Animal and Cellular Models.Biomedicines · 2026Review
- Myostatin in Obesity: A Molecular Link Between Metabolic Dysfunction and Musculotendinous Remodeling.International journal of molecular sciences · 2026Review
- Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer.Biomolecules · 2025Review
- Differential response of tissue engineered skeletal muscle from rheumatoid arthritis patients and healthy controls.Communications biology · 2025Article
- Aging: A struggle for beneficial to overcome negative factors made by muscle and bone.Mechanisms of ageing and development · 2025Review
- Association between chronic kidney disease and sarcopenia and emerging treatment strategies.Frontiers in nutrition · 2025Review
- Dietary polyphenols and sarcopenia: epigenetic mechanisms and geroscience perspectives for muscle health in aging.Frontiers in aging · 2025Review
- Exerkines and myokines in aging sarcopenia.Frontiers in endocrinology · 2025Review
- State-of-the-art insights into myokines as biomarkers of sarcopenia: a literature review.International journal of physiology, pathophysiology and pharmacology · 2025Review
- Association of triglyceride-glucose index and its related parameters with functional disability: evidence from the China Health and Retirement Longitudinal Study.Frontiers in aging neuroscience · 2025Article
- Investigation of the association between the triglyceride-glucose index and the incidence of frailty among middle-aged and older adults: evidence from the China health and retirement longitudinal study.Frontiers in public health · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The age-related loss of skeletal muscle (sarcopenia) is a major health concern as it is associated with physical disability, metabolic impairments, and increased mortality. The coexistence of sarcopenia with obesity, termed 'sarcopenic obesity', contributes to skeletal muscle insulin resistance and the development of type 2 diabetes, a disease prevalent with advancing age. Despite this knowledge, the mechanisms contributing to sarcopenic obesity remain poorly understood, preventing the development of targeted therapeutics. This article will discuss the clinical and physiological consequences of sarcopenic obesity and propose myostatin as a potential candidate contributing to this condition. A special emphasis will be placed on examining the role of myostatin signaling in impairing both skeletal muscle growth and insulin signaling. In addition, the role of myostatin in regulating muscle-to fat cross talk, further exacerbating metabolic dysfunction in the elderly, will be highlighted. Lastly, we discuss how this knowledge has implications for the design of myostatin-inhibitor clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.